Algocalmin, a painkiller, was the product boasting the highest sales in the first six months of this year, with 6.2 million packs sold, according to the date of IMS Health, a provider of information services for the healthcare industry. As there are around 6,000 retail pharmacies in Romania, each of them sold on average almost six packs of Algocalmin per day.
The second best-sold drug by volume is Nurofen, but over 1.5 million packs behind. Algocalmin won the battle against Nurofen even as the former changed its status at the beginning of this year, entering the category of prescription drugs.
At the same time, Algocalmin, part of the Zentiva portfolio, has a price advantage, costing less than 5 lei (a little above EUR1), while the price of Nurofen can go beyond RON13, according to pharmacy data.
The price gap is reflected in the value of the two products’ sales, with Nurofen’s standing at almost EUR15 million in the first six months of the year. On the other hand, Algocalmin, with just EUR7 million in sales, is not part of the ranking by value.
“While the shift to the category of prescription drugs implicitly means lower sales volumes on medium term, we’re confident the brand is going to be one of the best-selling analgesics in Romania in the future,” said Simona Cocos, general manager of Zentiva, a Sanofi company.
The ten best-selling drugs by volume registered sales of above 33 million packs in the first six months of this year, according to ZF calculations based on IMS Health data.
The first six months of this year brought a leader change in the ranking by value, with Seretide now holding the top position after Pegasys had previously held this position. Pegasys, used in the treatment of hepatitis, dropped to third place.
Dan Zamonea, general manager of Roche Romania, says these visible changes in the IMS ranking are mainly generated by the current context of the drug market.
Another Roche product, MabThera, climbed to second place in the general ranking. Overall, the company has four products in the ranking, which brought it sales of over EUR60 million in six months. Romania’s ten best-selling products brought around EUR150 million in the first half of this year, according to ZF calculations.
Aside from Nurofen, mainly used for pain and flu, the other products with the largest sales in Romania are used in the treatment of chronic diseases. Apart from Seretide, Enbrel and Remicade, which saw increases, the rest of top ten products registered sales drops (in value).
In July 2010-June 2011, the drug market expanded by 12% to EUR2.5 billion, according to IMS, a weaker performance, though, against the previous similar period.
“The trend points to a growth slowdown on a monthly basis, as a direct result to the problems in the system, but also of the falling purchasing power of patients,” said Corina Ciolan, general manager of IMS Health.
(English version by Catalina Apostoiu; Editing by Loredana Fratila-Cristescu)